AstraZeneca has struck a new AI-focused discovery deal with insitro, agreeing to pay $40 million upfront and up to $1.46 billion in development and commercial milestones to find novel drug targets for liver and heart diseases. Under the agreement, AstraZeneca will have exclusive worldwide rights to advance selected programs from the collaboration.
The work will focus on metabolic dysfunction-associated steatohepatitis, or MASH, and cardiomyopathies. Insitro said its platform combines human and cellular data with AI-enabled target identification to find causal disease biology, positioning the technology as a way to improve target selection rather than replace downstream drug development work.
Why This Deal Matters
For AstraZeneca, the transaction adds another external AI engine to a broader build-out that already includes a partnership with Algen Biotechnologies to find immunology targets, the acquisition of Modella AI, and an agentic AI licensing deal with Owkin. The pattern suggests the company is using AI across multiple layers of research strategy, with target discovery remaining a priority use case.
For insitro, the agreement continues a model it has used with several large biopharma companies. Gilead partnered with the company in 2019, Bristol Myers Squibb followed in 2020 and later extended and expanded that deal, and Eli Lilly teamed up with insitro in 2024 before a platform was made available to select biotechs in 2025. While these collaborations are financially backloaded, they still provide capital as insitro advances its own pipeline.
That pipeline now spans liver fat and fibrosis, obesity, neuroscience and ophthalmology, supported in part by the $400 million insitro raised in 2021. The commercial signal is that AI-native biotech platforms are still attracting large counterparties when they can tie computational methods to specific disease datasets and a clear handoff into conventional drug-development organizations.
In practical terms, AstraZeneca is paying relatively little upfront for optionality across two prevalent and underdiagnosed disease areas where high-content data may help uncover disease drivers. The test for this collaboration will be whether the platform yields targets AstraZeneca wants to carry forward, because that is where AI discovery deals move from narrative value to program value.
